Ontology highlight
ABSTRACT:
SUBMITTER: Loddick SA
PROVIDER: S-EPMC3769207 | biostudies-other | 2013 Sep
REPOSITORIES: biostudies-other
Molecular cancer therapeutics 20130716 9
Continued androgen receptor (AR) expression and signaling is a key driver in castration-resistant prostate cancer (CRPC) after classical androgen ablation therapies have failed, and therefore remains a target for the treatment of progressive disease. Here, we describe the biological characterization of AZD3514, an orally bioavailable drug that inhibits androgen-dependent and -independent AR signaling. AZD3514 modulates AR signaling through two distinct mechanisms, an inhibition of ligand-driven ...[more]